Skip to main content
INOVIQ LTD logo

INOVIQ LTD — Investor Relations & Filings

Ticker · IIQ ISIN · AU0000196149 ASX Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2016-06-16 Capital/Financing Update
Country AU Australia
Listing ASX IIQ

About INOVIQ LTD

https://www.inoviq.com

INOVIQ LTD specializes in the development and commercialization of next-generation exosome and precision diagnostics. The company focuses on innovative solutions for the early detection and monitoring of cancer and other diseases. Its proprietary technology portfolio includes EXO-NET, a high-throughput exosome capture tool designed for research and clinical applications, and the SubB2M platform, which utilizes an engineered protein to detect the pan-cancer biomarker Neu5Gc. The company also provides the hTERT test for bladder cancer monitoring. These technologies facilitate non-invasive liquid biopsy tests aimed at improving patient outcomes through high sensitivity and specificity. The core business activities encompass the creation of diagnostic tools and research reagents for the global healthcare and life sciences sectors, emphasizing precision medicine and early intervention.

Recent filings

Filing Released Lang Actions
Pro-forma Statement of Financial Position 1 page 23
Capital/Financing Update Classification · 85% confidence The document contains a pro-forma statement of financial position as at 31 December 2015, showing detailed financial data including assets, liabilities, and equity. The presence of a pro-forma financial statement indicates it is a financial report rather than an announcement or summary. However, the document length is only 1679 characters, which is quite short for a full financial report, but it contains substantive financial data and analysis. It is not an announcement of a report or a certification. The content aligns with a financial report but does not fit the typical Annual Report (10-K) or Interim Report (IR) exactly, as it is a pro-forma financial statement related to a public offer. Given the detailed financial data and the nature of the pro-forma financial position, the best fitting category is Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes, including pro-forma financial statements related to public offers.
2016-06-16 English
Use of Funds Information 1 page 238.9KB
Capital/Financing Update Classification · 95% confidence The document text primarily details the allocation and use of funds raised through a Public Offer, including specific amounts and percentages allocated to various expenses such as repayment of notes, costs for studies, salaries, intellectual property maintenance, and general working capital. There is no indication that this is a full financial report, audit, or earnings release. Instead, it is an update on capital raised and how it will be used, which aligns with a Capital/Financing Update. The document length is short (2137 characters), but it contains substantive financial allocation data rather than just an announcement or link to a report, so it is not a Report Publication Announcement or Regulatory Filing. Therefore, the best classification is Capital/Financing Update (CAP).
2016-06-16 English
Securities Trading Policy 4 pages 315.4KB
Governance Information Classification · 95% confidence The document is a detailed Securities Trading Policy for BARD1 Life Sciences Limited. It outlines rules and procedures for directors, employees, and associates regarding trading in the company's securities, including restrictions during closed periods, notification requirements, and definitions of inside information and exceptional circumstances. There is no financial data, earnings information, or report content. It is a governance-related policy document focused on insider trading and securities dealing compliance. This fits best under Governance Information (CGR) as it details internal rules and governance practices related to securities trading by insiders.
2016-06-16 English
Confirmation in relation to restricted securities 1
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to the Australian Securities Exchange regarding the escrow status of securities upon re-quotation. It specifies the escrow period and the types and quantities of shares involved. There is no financial data, no report attached or referenced, and no mention of management changes, voting results, or other report types. The content is an official regulatory announcement about securities escrow related to re-quotation, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2016-06-16 English
Terms of Securities 3 pages 424.4KB
Regulatory Filings
2016-06-16 English
Confirmations to ASX 2 pages 252.3KB
Board/Management Information Classification · 95% confidence The document is an announcement dated 16 June 2016 from BARD1 Life Sciences Limited regarding the satisfaction of conditions related to a public offer and vendor offer under a prospectus dated 7 April 2016. It confirms the completion of share allotments and acquisitions, updates on intellectual property agreements, ongoing audit status, no material subsequent events, compliance with ASX listing rules, and changes in the board of directors. The document is relatively short (3586 characters) and primarily provides updates and confirmations rather than detailed financial statements or comprehensive reports. It includes a section explicitly confirming board changes, which aligns with announcements about management or board changes. Therefore, the document fits best under the category of Board/Management Information (MANG).
2016-06-16 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.